Strengths

Johnson & Johnson’s diversified mix across MedTech, Innovative Medicine, and Consumer Health reduces single-product dependence versus peers, supporting steadier demand and earnings resilience.

The company’s 13.6% TTM ROIC indicates durable capital efficiency, outpacing many large-cap healthcare peers and reinforcing superior long-run value creation.

Its scale in regulated healthcare channels creates procurement, manufacturing, and distribution advantages that smaller peers cannot easily replicate, supporting margin durability.

A relatively conservative balance sheet versus highly levered healthcare peers preserves strategic flexibility for R&D, litigation management, and portfolio reshaping without stressing capital structure.

Weaknesses

A 139.8-day cash conversion cycle is long versus best-in-class healthcare peers, tying up working capital and limiting near-term cash efficiency.

The 1.09 current ratio and 0.81 quick ratio indicate only modest liquidity headroom, leaving less buffer than stronger peers during demand or reimbursement shocks.

Consumer Health separation reduced diversification benefits versus the pre-spin portfolio, making the remaining business mix more dependent on pharmaceutical and device execution.

Exposure to large, mature categories can constrain organic growth versus faster-growing specialty peers, which often benefit from higher innovation intensity and pricing power.

Opportunities

Pipeline execution in Innovative Medicine can lift growth versus slower-growing peers if new launches convert clinical depth into sustained commercial share gains.

MedTech expansion in higher-acuity procedures offers a larger addressable market than commoditized device segments, improving mix and supporting above-peer revenue growth.

Operational simplification after portfolio changes can improve working-capital discipline and cash generation, narrowing the efficiency gap versus leaner peers.

Further portfolio optimization could concentrate capital on higher-return franchises, strengthening long-term positioning versus peers with more fragmented business mixes.

Threats

Patent expirations and biosimilar competition can pressure Innovative Medicine more sharply than diversified peers with broader late-stage replacement pipelines.

Litigation and regulatory overhangs remain structurally important for JNJ, creating valuation and cash-flow uncertainty versus peers with lower legal exposure.

Pricing pressure from payers and governments can compress margins across pharmaceuticals and devices, especially versus peers with more differentiated or niche products.

Large-cap healthcare peers with faster innovation cycles can capture share in high-growth therapies and devices, challenging JNJ’s relative growth profile over time.

Overall Score

Johnson & Johnson remains structurally strong versus peers because of its scale, diversification, and capital efficiency, although working-capital drag and litigation risk temper the profile.